caa a22 4500 477127398 CHVBK 20180405111653.0 cr unu---uuuuu 170330e19970401xx s 000 0 eng 10.1023/A:1012043315093 doi (NATIONALLICENCE)springer-10.1023/A:1012043315093 Cytotoxicity of Solid Lipid Nanoparticles as a Function of the Lipid Matrix and the Surfactant [Elektronische Daten] [Rainer Müller, Dörte Rühl, Stephan Runge, Kai Schulze-Forster, Wolfgang Mehnert] Purpose. Assessment of the in vitro cytotoxicity of solid lipid nanoparticles (SLNs) as a function of lipid matrix (Dynasan 114, Compritol ATO 888), and stabilizing surfactant (poloxamers, Tween 80, soya lecithin, and sodium dodecyl sulphate). Comparison with other colloidal carriers should determine their potential use in the clinic. Methods. SLNs were produced by high pressure homogenisation. Cytotoxicity was assessed by measuring the viability of HL60 cells and human granulocytes after incubation with SLNs. Particle internalisation was quantified by chemiluminescence measurements. Results. The nature of the lipid had no effect on viability; distinct differences were found for the surfactants. Binding to the SLN surface reduced markedly the cytotoxic effect of the surfactants, e.g., up to a factor of 65 for poloxamer 184. The permanent HL60 cell line— differentiated from cells with granulocyte characteristics by retinoic acid treatment—yielded results identical to freshly isolated human granulocytes. In general, the SLNs showed a lower cytotoxicity compared to polyalkylcyanoacrylate and polylactic/glycolic acid (PLA/ GA) nanoparticles. Conclusions. Because the results are identical when using human granulocytes, differentiated HL60 cells can be used as an easily accessible in vitro test system for i.v. injectable SLN formulations. The SLNs appear suitable as a drug carrier system for potential intravenous use due to their very low cytotoxicityin vitro. Plenum Publishing Corporation, 1997 solid lipid nanoparticles nationallicence cytotoxicity nationallicence HL60 cells nationallicence poloxamer nationallicence Tween 80 nationallicence sodium dodecyl sulphate nationallicence Müller Rainer Department of Pharmaceutics, Biopharmaceutics & Biotechnology, The Free University of Berlin, Kelchstraβe 31, D-12169, Berlin aut Rühl Dörte Department of Pharmaceutics, Biopharmaceutics & Biotechnology, The Free University of Berlin, Kelchstraβe 31, D-12169, Berlin aut Runge Stephan Department of Pharmaceutics, Biopharmaceutics & Biotechnology, The Free University of Berlin, Kelchstraβe 31, D-12169, Berlin aut Schulze-Forster Kai Department of Pharmaceutical Biochemistry, The Free University of Berlin, Kelchstraβe 31, D-12169, Berlin aut Mehnert Wolfgang Department of Pharmaceutics, Biopharmaceutics & Biotechnology, The Free University of Berlin, Kelchstraβe 31, D-12169, Berlin aut Pharmaceutical Research Kluwer Academic Publishers-Plenum Publishers 14/4(1997-04-01), 458-462 0724-8741 14:4<458 1997 14 11095 https://doi.org/10.1023/A:1012043315093 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1012043315093 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Müller Rainer Department of Pharmaceutics, Biopharmaceutics & Biotechnology, The Free University of Berlin, Kelchstraβe 31, D-12169, Berlin aut NATIONALLICENCE 700 1- Rühl Dörte Department of Pharmaceutics, Biopharmaceutics & Biotechnology, The Free University of Berlin, Kelchstraβe 31, D-12169, Berlin aut NATIONALLICENCE 700 1- Runge Stephan Department of Pharmaceutics, Biopharmaceutics & Biotechnology, The Free University of Berlin, Kelchstraβe 31, D-12169, Berlin aut NATIONALLICENCE 700 1- Schulze-Forster Kai Department of Pharmaceutical Biochemistry, The Free University of Berlin, Kelchstraβe 31, D-12169, Berlin aut NATIONALLICENCE 700 1- Mehnert Wolfgang Department of Pharmaceutics, Biopharmaceutics & Biotechnology, The Free University of Berlin, Kelchstraβe 31, D-12169, Berlin aut NATIONALLICENCE 773 0- Pharmaceutical Research Kluwer Academic Publishers-Plenum Publishers 14/4(1997-04-01), 458-462 0724-8741 14:4<458 1997 14 11095 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer